Citigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59

Benzinga · 2d ago
Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $62 to $59.